Notice of Changes to PA-19-082, "Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R01 Clinical Trial Not Allowed)"

Notice Number: NOT-AI-19-026

Key Dates
Release Date: December 19, 2018

Related Announcements
PA-19-082

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute of Allergy and Infectious Diseases (NIAID) has made the following changes to PA-19-082, “Novel approaches to understand, prevent, treat and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R01 Clinical Trial Not Allowed)":

Currently Reads:

Part 1. Overview Information

Key Dates

AIDS Application Due Date(s)

Not Applicable

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Specific areas of research interest

Specific areas of research interest are focused on coccidioidomycosis, histoplasmosis and blastomycosis and include, but are not limited to:

  • Improve understanding of biology, transmission and pathogenesis of infection:
  • Improve understanding of pathogenesis
  • Expand understanding of the pathogen life cycle, including the role of climate and geography, host factors, physical and environmental factors that contribute to disease
  • Improve genotypic and phenotypic characterization associated with adverse clinical outcomes, and host immunity
  • Expand understanding of speciation and impact on clinical outcome
  • Identify/characterize host responses required for protection:
  • Determine the interaction of innate and adaptive immunity in response to infection
  • Identify immune markers associated with reduced disease severity
  • Elucidate mechanisms of protective immunity vs. those that ameliorate symptomatic disease
  • Support rational design of Coccidioides and other select endemic fungal pathogen vaccines:
  • Identify immunogens that elicit broad protection
  • Advance new vaccine approaches into preclinical models that exploit emerging antigen design strategies, novel technologies, and/or platforms
  • Define mechanisms and correlates of vaccine-induced protection
  • Test adjuvants and alternative delivery methods to enhance breadth and durability of immunity
  • Develop novel therapeutics to clear infection
  • Identify biomarkers that could inform disease progression and contribute to rapid diagnostics

This FOA will not support projects focused on HIV/AIDS.

Revised to Read:

Part 1. Overview Information

Key Dates

AIDS Application Due Date(s)

Standard AIDS dates apply, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
The first AIDS application due date for this FOA is May 7, 2019.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Specific areas of research interest

Specific areas of research interest are focused on coccidioidomycosis, histoplasmosis and blastomycosis and include, but are not limited to:

  • Improve understanding of biology, transmission and pathogenesis of infection:
  • Improve understanding of pathogenesis
  • Expand understanding of the pathogen life cycle, including the role of climate and geography, host factors, physical and environmental factors that contribute to disease
  • Improve genotypic and phenotypic characterization associated with adverse clinical outcomes, and host immunity
  • Expand understanding of speciation and impact on clinical outcome
  • Identify/characterize host responses required for protection:
  • Determine the interaction of innate and adaptive immunity in response to infection
  • Identify immune markers associated with reduced disease severity
  • Elucidate mechanisms of protective immunity vs. those that ameliorate symptomatic disease
  • Support rational design of Coccidioides and other select endemic fungal pathogen vaccines:
  • Identify immunogens that elicit broad protection
  • Advance new vaccine approaches into preclinical models that exploit emerging antigen design strategies, novel technologies, and/or platforms
  • Define mechanisms and correlates of vaccine-induced protection
  • Test adjuvants and alternative delivery methods to enhance breadth and durability of immunity
  • Develop novel therapeutics to clear infection
  • Identify biomarkers that could inform disease progression and contribute to rapid diagnostics

This FOA will not support projects focused solely on HIV/AIDS.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Dona Love, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-761-7788
Email: dona.love@nih.gov